Navigation Links
Arena Pharmaceuticals Announces Public Offering of Common Stock
Date:7/7/2009

SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on November 25, 2008, which became effective on December 3, 2008. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contact:  Jack Lief
              President and CEO

              Robert E. Hoffman
              VP, Finance and CFO
              Arena Pharmaceuticals, Inc.
              858.453.7200, ext. 222

www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
3. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
4. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
5. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
8. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
11. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... (PRWEB) May 19, 2013 According ... Market Analysis and Forecast (2013 – 2018): By ... Defense, Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, ... of image sensor market was $8.00 billion in ... in 2018, at an estimated CAGR of 3.84% ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... 19, 2013 Vegas Hotel Escapes, the ... to announce the launch it's all new vacation packages ... Grand on 5/19/2013. Consumers traveling to Las Vegas will ... available on VegasHotelEscapes.com's website. Travelers will be pleased to ... competitors price. , Vegas Hotel Escapes specializes in helping ...
(Date:5/19/2013)... IL (PRWEB) May 19, 2013 Beginning Wednesday, ... River Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" ... Belvidere. RRVBC will provide hot dogs and all the ... ice-cold slushies each day throughout the summer. “Donors are our ... maintain a stable and adequate blood supply. This is ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... fears of anxiety-ridden fathers are passed on to the ... As many as 65 women were studied by the ... at this conclusion. ,This increased the pain ... affect their immediate recovery and factors such as breastfeeding ...
... new research conducted by Derek Griffiths, Ph.D., professor of geriatric ... bladder// control is due to the reduced activity of the ... his findings in a recent issue of the Journal of ... (fMRI) technology. , He analyzed the brain activity ...
... In UK deaths due to heart disease is on the rise. ... problems//. ,Hence The National Council for Health and Clinical ... from heart disease with statins. ,It is estimate that ... heart problem in the next 10 years. ,The National ...
... Public Health are of the opinion that the decision by almost ... presence of West Nile Virus is not a feasible option. ... very recently developed tests. This means that screening donated blood to ... order to avoid future infections. But the point is that many ...
... Southampton General Hospital, studied the inflammatory response in occupational ... at studying the environmental risk of developing infections and ... ,Researchers found that the inflammatory response in Metal ... persons and an absence of an immune response shows ...
... the soil can be used to clean the land which ... to the University of York. The team led by the ... Isolated a bacterial micro- // organism in the soil in ... a source of nitrogen for growth. ,However, ...
Cached Medicine News:
(Date:5/17/2013)... 2013  Sony Biotechnology Inc. ("Sony") today announced the launch ... 130um sorting chip.  Sony will also be exhibiting its newly ... Cell Sorter, the EC800 flow cytometer, and new SP6800 Spectral ... which will be held at the San Diego ... , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... 2011 ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Citi 2011 Global Healthcare Conference ... conference is being held at the Hilton New York Hotel ... and chief financial officer, of ViroPharma, will present at the ...
... Feb. 28, 2011 Rock Creek Pharmaceuticals, a wholly ... CIGX ) has been notified by the Roskamp Institute ... review board (IRB) approval to conduct a three-month, multi-site ...  The study (referred to as the "Flint Study"), will ...
Cached Medicine Technology:ViroPharma to Participate in Two March Healthcare Conferences 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 2Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 3Roskamp Institute Obtains IRB Approval for Multi-Site Human Clinical Trial with Rock Creek Pharmaceutical RCP-006 Compound 4
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 900 high frequency desiccator forever removes the need to go through a tedious multi-step process to change from low to high power....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: